Gene Therapy Strategies for Alzheimer's Disease: An Overview
Abstract
Key neuropathological hallmarks of Alzheimer's disease (AD) are extracellular amyloid plaques and intracellular accumulation of hyperphosphorylated Tau protein. The mechanisms underlying these neuropathological changes remain unclear. So far, research on AD therapy has had limited success in terms of symptomatic treatments although it has also had several failures for disease-modifying drugs. Gene transfer strategies to the brain have contributed to evaluate in animal models many interesting tracks, some of which should deserve clinical applications in AD patients in the future.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
One strategy to prevent Alzheimer's disease in APOE4 carriers is to modify the central nervous system genetically to express APOE2, providing the CNS with the protective APOE2 to balance the Alzheimer's disease risk associated with expression of APOE4.
“Based on these observations, one strategy to prevent AD in APOE4 carriers is to modify the central nervous system (CNS) genetically to express APOE2, providing the CNS with the protective APOE2 to balance the AD risk associated with expression of APOE4.22–26”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [22]
The citation lists haven’t been fetched yet
References 61 · Cited by 45
- Authors
- Alves, S., Fol, R., & Cartier, N.
- Affiliations
- Université Paris-Sud (FR)
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2016-02
- Volume
- 27
- Issue
- 2
- Pages
- 100-107
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2281605478
- Cited by
- 45
- References
- 61
- Citations by year
- 2026: 1 · 2024: 11 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 7 · 2019: 6 · 2018: 5 · 2017: 2 · 2016: 1
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-MALZ-0103)
- Fondation pour la Recherche Médicale
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, gene therapy, amyloid plaques, hyperphosphorylated tau, disease-modifying drugs, symptomatic treatment, animal models of Alzheimer's disease, clinical translation
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain, Clinical Trials as Topic, Disease Models, Animal, Humans, Somatomedins, Genetic Therapy, Lentivirus, Aspartic Acid Endopeptidases, Disease Progression, Brain-Derived Neurotrophic Factor, RNA, Small Interfering, NF-E2-Related Factor 2, Amyloid Precursor Protein Secretases, Antibodies, Neutralizing, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
